威华达控股(00622) - 2024 - 年度财报
2025-04-28 10:09
Annual Report 2024 1 威華達控股有限公司 年度報告2024 目錄 | | 頁次 | | --- | --- | | 公司資料 | 2 | | 管理層論述及分析 | 3 | | 董事及公司秘書履歷 | 14 | | 董事會報告 | 17 | | 企業管治報告 | 30 | | 環境、社會及管治報告 | 45 | | 獨立核數師報告書 | 79 | | 綜合損益及其他全面收益表 | 85 | | 綜合財務狀況表 | 87 | | 綜合權益變動表 | 89 | | 綜合現金流量表 | 91 | | 綜合財務報表附註 | 93 | | 財務概要 | 176 | 2 威華達控股有限公司 年度報告2024 公司資料 董事會 執行董事 沈慶祥先生 (主席) 黄蘊文女士 王溢輝先生 獨立非執行董事 陳克勤先生, S.B.S.,J.P. 洪祖星先生, B.B.S. 藍章華先生 余仲良先生 授權代表 黄蘊文女士 王溢輝先生 審核委員會 陳克勤先生, S.B.S.,J.P. 洪祖星先生, B.B.S . 藍章華先生 余仲良先生 (主席) 提名委員會 陳克勤先生, S.B.S.,J.P. 洪祖星先生, B.B.S ...
优趣汇控股(02177) - 2024 - 年度财报
2025-04-28 10:09
ANNUAL REPORT 年 報 2024 Annual Report 2024 年報 目錄 | 2 | 公司簡介 | | --- | --- | | 3 | 公司資料 | | 5 | 主席致辭 | | 8 | 管理層討論及分析 | | 16 | 董事及高級管理層履歷詳情 | | 21 | 董事會報告 | | 37 | 企業管治報告 | | 53 | 獨立核數師報告 | | 58 | 綜合全面收入表 | | 60 | 綜合資產負債表 | | 62 | 綜合權益變動表 | | 63 | 綜合現金流量表 | | 64 | 綜合財務報表附註 | | 144 | 五年財務概要 | | 145 | 釋義 | 公司簡介 優趣匯控股有限公司是中國領先的品牌電子商務運營服務商,專注於快速消費品,包括成人個人護理產品、嬰幼兒個 人護理產品、美妝產品、健康產品及其他等產品品類。我們與包括尤妮佳集團蘇菲、moony等品牌,菲婷絲集團品牌包 括水之密語、可悠然、惠潤、FINO等品牌,高絲集團Kose Cosmeport品牌,小林製藥,太田胃散,大正製藥,安速等 約60個品牌開展合作,為其提供全渠道、一站式、高增值的運營及定制化服務 ...
中国建筑兴业(00830) - 2024 - 年度财报
2025-04-28 10:07
Financial Performance - Revenue for 2024 is projected to be HK$8,101,694, a decrease of 6.5% from 2023's HK$8,665,765[11] - Profit attributable to owners of the Company for 2024 is expected to reach HK$650,253 million, reflecting a growth of 12% from 2023's HK$580,420 million[11] - Basic earnings per share for 2024 are expected to be HK$28.83, an increase from HK$25.73 in 2023[11] - In 2024, the Group's principal business revenue reached HK$8,102 million, with a profit attributable to shareholders of HK$650 million, representing a year-on-year increase of 12.0%[110] - Earnings per share for 2024 amounted to HK28.83 cents, reflecting a year-on-year increase of 12.0%[110] - Total dividends distributed for the year were HK9.8 cents per share, marking a year-on-year increase of 12.6%[110] - The Group's total revenue decreased by 6.5% to HK$8,102 million for the year ended December 31, 2024, compared to HK$8,666 million in 2023[150] - Profit attributable to owners increased to HK$650 million, up 12.0% from HK$580 million in 2023, with basic earnings per share rising to HK28.83 cents from HK25.73 cents[150] Assets and Liabilities - Total assets increased to HK$11,502,371 million in 2024, up from HK$10,641,662 million in 2023, representing a growth of 8.1%[11] - As of December 31, 2024, the Group had cash and bank balances of HK$983 million, an increase from HK$713 million in 2023, while total borrowings rose to HK$1.58 billion from HK$1.19 billion[164] - The Group's net gearing ratio as of December 31, 2024, was approximately 23.4%, up from 20.7% in 2023, indicating a higher level of debt relative to net assets[164] - The Group recorded a cumulative new contract amount of HK$11.02 billion for the year ended December 31, 2024, with a backlog of contracts amounting to approximately HK$34.02 billion, including unfinished contracts of about HK$18.53 billion[162] Market and Project Developments - The Company has expanded into overseas markets with the incorporation of Far East Facade (Singapore) Pte. Ltd. in January 2024[23] - In April 2024, the Company won the bid for the facade project of New Central Site 3A, a significant international-level project in Hong Kong[33] - The Company achieved a first-place ranking in Tencent Group's third-party safety assessment for 14 consecutive months during the construction of the Tenova future project[35] - Major new projects awarded included the New Central Harbourfront 3A Commercial Project and the Kwu Tung North residential project, contributing to the Group's strong performance in Hong Kong[114] - The Galaxy (phase 4) project in Macau, the largest single facade contract globally, is progressing smoothly and meeting its phased targets[115] - The Group is focusing on the facade market development along the "Belt and Road" initiative, with plans to explore large potential projects in the Middle East and Southeast Asia[121][123] Sustainability and Innovation - The Company was awarded the "Hong Kong Green Organisation Certification" for the eighth consecutive year, highlighting its commitment to sustainability[19] - In May, the newly established Far East Photovoltaic Technology (Guangdong) Company Limited will focus on research and development of building integrated photovoltaic (BIPV) products[41] - The Group plans to enhance its facade business through building-integrated photovoltaics (BIPV), with ongoing projects in Hong Kong and the Chinese Mainland[137] - The Group is committed to sustainability and will continue to deepen climate risk management initiatives and enhance technology research and development for BIPV projects[139] - The project BIM Design Team won the Gold Award in the 2024 Seventh "Youlu Cup" National BIM Technology Competition, highlighting the company's commitment to innovation in construction technology[83][84] Corporate Governance and Leadership - Mr. Zhu Haiming was appointed as Executive Director and CEO on June 1, 2024, bringing over 18 years of experience in construction engineering management and infrastructure investment[184] - Mr. Wong Man Cheung, appointed as Executive Director and CFO on July 1, 2022, has over 28 years of experience in accounting, financial management, and corporate financing[188] - The company is focused on sustainability, with key members of the board involved in the Sustainability Committee[187][191] - The board comprises a diverse group of professionals with extensive experience across various sectors, including construction, finance, and legal services[187][194] - The company aims to enhance its corporate governance through the expertise of its independent directors[191] Operational Performance - The facade and general contracting business segment's revenue decreased by 6.4% to HK$7,224 million, with gross profit down 2.4% to HK$862 million and operating profit down 4.0% to HK$782 million[153] - The operating management business segment's revenue decreased to HK$877 million, while operating profit increased to HK$56 million due to effective cost control measures[154] - Administrative, selling, and other operating expenses decreased to HK$210 million from HK$288 million in 2023, reflecting improved cost management[156] - Finance costs decreased to HK$75 million from HK$82 million in 2023, attributed to stringent finance cost control measures[156] Employee and Workforce - The Group employed a total of 4,006 employees as of December 31, 2024, down from 4,498 employees in 2023[178]
新丰泰集团(01771) - 2024 - 年度财报
2025-04-28 10:07
2024 年 報 2024 ANNUAL REPORT Sun fonda Group H oldings Limite d 新豐泰集團控股有限公司 Annual Re port 2024 年報 目錄 | 公司資料 | 2 | | --- | --- | | 財務摘要 | 4 | | 董事會主席致辭 | 6 | | 管理層討論與分析 | 8 | | 董事、高級管理層和公司秘書簡歷 | 34 | | 企業管治報告 | 41 | | 董事會報告 | 64 | | 環境、社會及管治報告 | 82 | | 獨立核數師報告 | 114 | | 綜合損益表 | 120 | | 綜合全面收益表 | 121 | | 綜合財務狀況表 | 122 | | 綜合權益變動表 | 124 | | 綜合現金流量表 | 125 | | 財務報表附註 | 127 | | 財務概要 | 208 | 1 新豐泰集團控股有限公司 年度報告 2024 公司資料 公司中文名稱 新豐泰集團控股有限公司 公司英文名稱 Sunfonda Group Holdings Limited 投資者查詢 電話:+852 2565 9898 傳真:+852 2565 ...
千百度(01028) - 2024 - 年度财报
2025-04-28 10:07
千百度國際控股有限公司 C. banner International Holdings Limited Stock Code 股份代號 : 1028 (Incorporated in Bermuda with limited liability) (於百慕達註冊成立之有限公司) Annual Report 年度報告 2024 Contents 目錄 Report of the Directors 董事會報告 15 Management Discussion and Analysis 管理層討論及分析 30 Corporate Governance Report 企業管治報告 53 Directors and Senior Management 董事及高級管理層 77 Environmental, Social and Governance Report 環境、社會及管治報告 82 | Independent Auditor's Report | | | --- | --- | | 獨立核數師報告 | 186 | | Consolidated Statement of Profit or Loss | | | ...
励晶太平洋(00575) - 2024 - 年度财报
2025-04-28 10:06
CONTENTS 目 錄 | 2 | Performance Overview | 業績概覽 | | --- | --- | --- | | 4 | Chairman's Statement | 主席報告 | | 7 | Directors' Report | 董事會報告 | | 31 | Biographical Details of Directors and | 董事及高級管理層 | | | Senior Management | 之履歷詳情 | | 38 | Management's Discussion and Analysis | 管理層對本集團業績 | | | of the Group's Performance | 之討論及分析 | | 50 | Corporate Governance Report | 企業管治報告 | | 82 | Environmental, Social and Governance Report | 環境、社會及管治報告 | | 113 | Independent Auditor's Report | 獨立核數師報告 | | 119 | Consolidated S ...
欧康维视生物-B(01477) - 2024 - 年度财报
2025-04-28 10:05
(Incorporated in the Cayman Islands with limited liability) ( 於開曼群島註冊成立的有限公司 ) Stock code 股份代號 : 1477 2024 ANNUAL REPORT 年度報告 Virtus et Virtus et Lumen 勇氣和光明 目錄 | 公司資料 | 2 | | --- | --- | | 主席致辭 | 4 | | 財務概要 | 6 | | 管理層討論及分析 | 8 | | 董事及高級管理層概覽 | 22 | | 企業管治報告 | 30 | | 董事會報告 | 47 | | 獨立核數師報告 | 78 | | 綜合損益及其他全面收益表 | 85 | | 綜合財務狀況表 | 86 | | 綜合權益變動表 | 87 | | 綜合現金流量表 | 88 | | 綜合財務報表附註 | 90 | | 釋義及縮略詞 | 155 | 公司資料 董事會 執行董事 Ye LIU先生 (首席執行官) 胡兆鵬博士 非執行董事 審核委員會 胡定旭先生 (主席) 黃翼然先生 張振宇先生 薪酬委員會 張振宇先生 (主席) 胡定旭先生 黃翼然先生 提名委員 ...
南京熊猫电子股份(00553) - 2025 Q1 - 季度财报
2025-04-28 10:03
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責,對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明,並 明 確 表 示,概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 2025年第一季度報告 重要提示 – 1 – 1. 南 京 熊 猫 電 子 股 份 有 限 公 司(「本公司」或「公 司」)董 事 會(「董事會」)、 監事會及董事、監事、高級管理人員保證季度報告內容的真實、準確、 完 整,不 存 在 虛 假 記 載、誤 導 性 陳 述 或 者 重 大 遺 漏,並 承 擔 個 別 和 連 帶 的 法 律 責 任。 2. 公司負責人胡回春、主管會計工作負責人胡壽軍及會計機構負責人(會 計 主 管 人 員)薛 剛 保 證 季 度 報 告 中 財 務 報 表 的 真 實、準 確、完 整。 3. 本 公 司 第 一 季 度 報 告 未 經 審 計。 一. 主要財務數據 (一)主要會計數據和財務指標(按中華人民共和國企業會計準則編製, 未 經 審 核) 單 位:元 幣 種:人 民 幣 本報告期比 | | 本報告期 ...
纽曼思(02530) - 2024 - 年度财报
2025-04-28 10:03
Numans Health Food Holdings Company Limited 紐曼思健康食品控股有限公司 (於開曼群島註冊成立的有限公司) 股份代號:2530 2024 年報 Numans Health Food Holdings Company Limited (Incorporated in the Cayman Islands with limited liability) Stock code : 2530 2024 ANNUAL REPORT 紐曼思健康食品控股有限公司 Numans Health Food Holdings Company Limited ANNUAL REPORT 年報 2024 | 目錄 | | --- | | 2 | 公司資料 | | --- | --- | | 3 | 主席致辭 | | 4 | 管理層討論及分析 | | 10 | 董事、高級管理層及公司秘書簡歷 | | 20 | 董事會報告 | | 34 | 企業管治報告 | | 51 | 環境、社會及管治報告 | | 73 | 獨立核數師報告 | | 79 | 綜合損益及其他全面收益表 | | 80 | 綜合財務 ...
康宁杰瑞制药-B(09966) - 2024 - 年度财报
2025-04-28 10:01
ALPHAMAB ONCOLOGY 康寧傑瑞生物製藥 (於開曼群島註冊成立的有限公司) 股份代號 : 9966 2024 年度報告 目錄 | | 頁次 | | 頁次 | | --- | --- | --- | --- | | 公司簡介 | 2 | 董事會報告 | 61 | | 公司資料 | 5 | 獨立核數師報告 | 99 | | 董事長寄語 | 8 | 綜合損益及其他全面收益表 | 104 | | 釋義及技術詞彙 | 10 | 綜合財務狀況表 | 105 | | 財務摘要 | 19 | 綜合權益變動表 | 107 | | 業務摘要 | 20 | 綜合現金流量表 | 109 | | 管理層討論與分析 | 25 | 綜合財務報表附註 | 111 | | 董事及高級管理層履歷 | 38 | 財務概要 | 204 | | 企業管治報告 | 44 | | | 1 康寧傑瑞生物製藥 2024年度報告 公司簡介 概覽 我們是一家中國領先的生物製藥公司,在ADC、雙特異性抗體和多功能蛋白質工程方面擁有完善的專有技 術平台。通過運用我們特有的藥物發現及開發能力,為全球患者提供世界一流的創新治療用生物製劑。我 們認為該等能力可 ...